Answers are grounded in this paper and cite their sources.
For the last 20 years, erythropoiesis-stimulating agents have transformed the lives of renal dialysis patients, and they are now being used to correct anaemia in chronic kidney disease and after renal transplantation. In future, these drugs may be used outside the renal clinic to improve outcomes in patients with chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Richard Fluck (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: